Welcome To PTX

PTX is a clinical stage life-science company focused on the development of therapies that prevent the toxic consequences of chemotherapy and muscle cramps during dialysis. PTX has multiple product candidates in development that are based on molecules with well-known safety profiles. PTX is based on Boston, a world-renowned biotech hub. The management team has worked together in successful startups and each member has decades of experience in product development and gaining FDA approvals.

James Wilkie

Founder & CEO

James Wilkie has 38 years of experience in the life sciences industry developing both drugs and devices. Jim was the co-founder and CEO of Lowell Therapeutics, which was acquired by AcelRx Pharmaceuticals in 2022. He joined La Jolla Pharmaceutical Co. in 2014 as the VP of New Enterprise Development responsible for identifying New Drug Candidates and he spun out Lowell Therapeutics. Prior to joining LJPC, Jim served as COO of Pluromed, Inc., until the sale of the company in 2012 to Sanofi. He joined Pluromed in 2005 as VP of Operations and led the development team to commercialize two successful products in the U.S. and Europe, where he was responsible for the overall operation. Prior to his experience at Pluromed, he held various positions of increasing responsibility at MedChem Products, Inc., including Director of Engineering for 3 sites. Upon the sale of MedChem to C. R. Bard, he spun-off certain technology and co-founded Surgical Sealants, Inc. He holds 4 issued patents and several pending applications. Jim received his B.S. in Engineering from the University of Massachusetts in 1985.

Lakhmir Chawla, MD

Founder, Chairman, & CMO

Dr. Chawla led the development and FDA approval of Giapreza, an ICU drug with 14 issued patents and $40 million revenue. He was Professor of Medicine at George Washington University where he held dual appointments in the Department of Anesthesiology and Critical Care Medicine. Dr. Chawla was the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. He received the International Vicenza Award for Critical Care Nephrology in June 2015, which recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide. Dr. Chawla was selected as the recipient of the Vicenza Award for his contributions to the development of the renal angina model, the development and standardization of the furosemide stress test, the link between AKI and chronic kidney disease (CKD), and the use of angiotensin II in the treatment of high-output shock. He is an internationally renowned expert in the field of AKI and is an active investigator in the fields of inflammation and AKI, AKI biomarkers, AKI risk prediction, chronic kidney disease caused by AKI and AKI therapeutics. Dr. Chawla is the author of over 100 peer-reviewed publications and was previously an Associate Editor for the Clinical Journal of the American Society of Nephrology.

Arthur Atkinson, MD

Founder & CSO

Dr. Atkinson received his A.B. degree in Chemistry from Harvard College in 1959 and his M.D. from Cornell University Medical College in 1963. While at Northwestern, he and his colleagues set up the first laboratory devoted to drug monitoring, conducted the first clinical investigations to develop the acetylated metabolite of procainamide as an antiarrhythmic drug, carried out the first PK studies with stable isotope-labeled drugs, and completed basic research that elucidated the physiologic basis of some multicompartmental models of drug distribution. In 1994, Dr. Atkinson was appointed Corporate VP for Clinical Development and Medical Affairs at Upjohn. Following the Upjohn-Pharmacia merger, he joined the Center for Drug Development Science at Georgetown University as an Adjunct Professor of Pharmacology. From 1975 to 1979, Dr. Atkinson served as a member of the Pharmacology/Toxicology Program Committee of the National Institute of General Medical Sciences (NIGMS), and from 1984 to 1986, chaired the Pharmacological Sciences Program Committee for that institute. In 1997, he returned to NIH as a Special Expert Consultant in Clinical Pharmacology for NIGMS. He was appointed Senior Advisor in Clinical Pharmacology to the Director of the NIH Clinical Center where he directed the ClinPRAT postdoctoral training program and the Clinical Center course on Principles of Clinical Pharmacology. Dr. Atkinson is a Master of the American College of Physicians (MACP) and has been President of the Chicago Society of Internal Medicine, President of the American Board of Clinical Pharmacology, and President of the American Society for Clinical Pharmacology and Therapeutics. He serves as an Emeritus Associate Editor of Clinical Pharmacology and Therapeutics and Emeritus Editor of Translational and Clinical Pharmacology. He has served as an editor for all four editions of the Principles of Clinical Pharmacology textbook, which in the fourth edition was re-named Atkinson’s Principles of Clinical Pharmacology. He received the Harry Gold Award from ASPET, the Oscar Hunter Award from ASCPT, and the Award in Excellence from the PhRMA Foundation.

Welcome to PTX, Your Partner in Transforming Cancer Care

At PTX, we are driven by a profound commitment to revolutionize cancer treatment by alleviating the toxic side effects of chemotherapy. Based in the vibrant city of Boston, a hub of innovation and scientific excellence, our biotech company is dedicated to pioneering advancements that make a meaningful impact on the lives of cancer patients and their families.

Our mission is clear – to enhance the quality of life for individuals undergoing chemotherapy by developing innovative solutions that address the toxic side effects associated with this life-saving treatment. We believe in a future where patients can focus on their journey to recovery without the burden of debilitating side effects.

At the heart of PTX is our unwavering commitment to cutting-edge research and development. Our team of world-class scientists, researchers, and experts collaborate tirelessly to explore groundbreaking approaches to mitigate the adverse effects of chemotherapy. Through relentless innovation, we strive to redefine the landscape of cancer care.

As we continue to push the boundaries of possibility, we invite you to join us on this transformative journey. Whether you are a patient seeking relief, a healthcare professional exploring new avenues, a collaborator in the scientific community, or an investor that wants to take part in creating solutions, we welcomes your partnership in redefining the future of cancer care.

About PTX-501

Patients with chronic kidney failure that undergo dialysis may experience muscle cramps due to the rapid withdrawal of fluid, which is the general purpose of the procedure. However, these muscle cramps can be painful and may cause the patient to prematurely discontinue therapy. PTX-501 is designed to prevent muscle cramps in patients undergoing dialysis. PTX is conducting a Phase 1b study in Australia. PTX-501 is eligible for the Transitional Drug Add-On Payment Adjustment (TDAPA), which supports payment and patient access to new therapies introduced to the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). 

Client Testimonials

“A testimonial from a client who loves your food. Testimonials can be a highly effective way of establishing credibility and improving your restaurants reputation.”
Client Name
“A testimonial from a client who loves your food. Testimonials can be a highly effective way of establishing credibility and improving your restaurants reputation.”
Client Name
“A testimonial from a client who loves your food. Testimonials can be a highly effective way of establishing credibility and improving your restaurants reputation.”
Client Name

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

OK